neuromuscular

Dyne Therapeutics will present key advancements in its neuromuscular pipeline at the 2026 MDA Conference. Updates will focus on its FORCE™ platform for genetic muscle diseases like DMD and DM1, highlighting progress in clinical trials, safety, and efficacy. These presentations are anticipated to showcase Dyne’s innovative gene therapy approach and its potential impact on treating rare neuromuscular conditions.